Initial Statement of Beneficial Ownership (3)
26 October 2019 - 3:53AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Blum Susan |
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/17/2019
|
3. Issuer Name and Ticker or Trading Symbol
MELINTA THERAPEUTICS, INC. /NEW/ [MLNT]
|
|
(Last)
(First)
(Middle)
C/O MELINTA THERAPEUTICS, INC., 300 TRISTATE INTERNATIONAL, SUITE 272 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
VP of Finance & CAO / |
|
(Street)
LINCOLNSHIRE, IL 60069
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Melinta Common Stock | (1) | 3/21/2026 | Melinta Stock Option (right to buy) | 877.0 | $190.0 | D | |
| Melinta Common Stock | (2) | 8/7/2027 | Melinta Stock Option (right to buy) | 80.0 | $104.85 | D | |
| Melinta Common Stock | (3) | 4/19/2028 | Melinta Stock Option (right to buy) | 4000.0 | $37.25 | D | |
| Melinta Common Stock | (4) | (4) | Melinta Restricted Stock Units | 25000.0 | (4) | D | |
| Explanation of Responses: |
| (1) | Shares will vest 25% on the first anniversary of the award, March 22, 2017, then ratably over the following 36 months. |
| (2) | Shares will vest 25% on the first anniversary of the award, August 8, 2018, then ratably over the following 36 months. |
| (3) | Shares will vest 25% on the first anniversary of the award, April 18, 2019, then ratably over the following 36 months. |
| (4) | The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Blum Susan
C/O MELINTA THERAPEUTICS, INC.
300 TRISTATE INTERNATIONAL, SUITE 272
LINCOLNSHIRE, IL 60069 |
|
| VP of Finance & CAO |
|
Signatures
|
| /s/ Russell E Causey, by Power of Attorney | | 10/25/2019 |
| **Signature of Reporting Person | Date |
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Melinta Therapeutics Inc (NASDAQ): 0 recent articles
More Melinta Therapeutics, Inc. /new/ News Articles
